SPY757.55+0.06%QQQ688.55+0.06%BTC/USD71,366.40−3.46%DIA522.45−0.00%GLD355.38+0.14%TLT79.70−0.03%

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc.

HEPAOTCQB

Trade with Public

$0.1400

-0.18-55.97%

Last update: Nov 12, 3:05 PM

Overview News Charts Earnings ForecastPrice TargetsFinancials Sentiment Ownership Compare

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. (HEPA) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. (HEPA) stock.

Analyst Consensus — 1 Analysts

1Hold

# Analysts1

Latest Upgrades and Downgrades for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Brookline Capital	Kumaraguru Raja	Downgrade	Buy→Hold	—

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc.

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. (HEPA) Stock Price Target 2026

Latest Upgrades and Downgrades for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. Stock

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. (HEPA) Stock Price Target 2026

Latest Upgrades and Downgrades for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. Stock

Analyst Ratings News

PRO
Brookline Capital Downgrades Hepion Pharmaceuticals to Hold

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022

PRO
Cantor Fitzgerald Initiates Coverage On Hepion Pharmaceuticals with Overweight Rating, Announces Price Target of $3.5

PRO
UPDATE: Hearing Roth Capital Has Buy Rating, $9 Price Target On Hepion Pharma

PRO
Hepion Pharma Shares Spike To Session High, Up 58%; Hearing Roth Capital Highlights Strong Rationale For Non-Immunosuppressive Molecule Like Co.'s CRV431 Showing Some Anti-Viral, Anti-Fibrotic Effect On Coronavirus Infection

PRO
Brookline Capital Initiates Coverage On Hepion Pharmaceuticals with Buy Rating, Announces $12 Price Target

Analyst Ratings News

PRO
Brookline Capital Downgrades Hepion Pharmaceuticals to Hold

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022

PRO
Cantor Fitzgerald Initiates Coverage On Hepion Pharmaceuticals with Overweight Rating, Announces Price Target of $3.5

PRO
UPDATE: Hearing Roth Capital Has Buy Rating, $9 Price Target On Hepion Pharma

PRO
Hepion Pharma Shares Spike To Session High, Up 58%; Hearing Roth Capital Highlights Strong Rationale For Non-Immunosuppressive Molecule Like Co.'s CRV431 Showing Some Anti-Viral, Anti-Fibrotic Effect On Coronavirus Infection

PRO
Brookline Capital Initiates Coverage On Hepion Pharmaceuticals with Buy Rating, Announces $12 Price Target

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc.

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. (HEPA) Stock Price Target 2026

Latest Upgrades and Downgrades for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. Stock

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. (HEPA) Stock Price Target 2026

Latest Upgrades and Downgrades for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. Stock

Analyst Ratings News

PROBrookline Capital Downgrades Hepion Pharmaceuticals to Hold

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022

PROCantor Fitzgerald Initiates Coverage On Hepion Pharmaceuticals with Overweight Rating, Announces Price Target of $3.5

PROUPDATE: Hearing Roth Capital Has Buy Rating, $9 Price Target On Hepion Pharma

PROHepion Pharma Shares Spike To Session High, Up 58%; Hearing Roth Capital Highlights Strong Rationale For Non-Immunosuppressive Molecule Like Co.'s CRV431 Showing Some Anti-Viral, Anti-Fibrotic Effect On Coronavirus Infection

PROBrookline Capital Initiates Coverage On Hepion Pharmaceuticals with Buy Rating, Announces $12 Price Target

Analyst Ratings News

PROBrookline Capital Downgrades Hepion Pharmaceuticals to Hold

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022

PROCantor Fitzgerald Initiates Coverage On Hepion Pharmaceuticals with Overweight Rating, Announces Price Target of $3.5

PROUPDATE: Hearing Roth Capital Has Buy Rating, $9 Price Target On Hepion Pharma

PROHepion Pharma Shares Spike To Session High, Up 58%; Hearing Roth Capital Highlights Strong Rationale For Non-Immunosuppressive Molecule Like Co.'s CRV431 Showing Some Anti-Viral, Anti-Fibrotic Effect On Coronavirus Infection

PROBrookline Capital Initiates Coverage On Hepion Pharmaceuticals with Buy Rating, Announces $12 Price Target

PRO
Brookline Capital Downgrades Hepion Pharmaceuticals to Hold

PRO
Cantor Fitzgerald Initiates Coverage On Hepion Pharmaceuticals with Overweight Rating, Announces Price Target of $3.5

PRO
UPDATE: Hearing Roth Capital Has Buy Rating, $9 Price Target On Hepion Pharma

PRO
Hepion Pharma Shares Spike To Session High, Up 58%; Hearing Roth Capital Highlights Strong Rationale For Non-Immunosuppressive Molecule Like Co.'s CRV431 Showing Some Anti-Viral, Anti-Fibrotic Effect On Coronavirus Infection

PRO
Brookline Capital Initiates Coverage On Hepion Pharmaceuticals with Buy Rating, Announces $12 Price Target

PRO
Brookline Capital Downgrades Hepion Pharmaceuticals to Hold

PRO
Cantor Fitzgerald Initiates Coverage On Hepion Pharmaceuticals with Overweight Rating, Announces Price Target of $3.5

PRO
UPDATE: Hearing Roth Capital Has Buy Rating, $9 Price Target On Hepion Pharma

PRO
Hepion Pharma Shares Spike To Session High, Up 58%; Hearing Roth Capital Highlights Strong Rationale For Non-Immunosuppressive Molecule Like Co.'s CRV431 Showing Some Anti-Viral, Anti-Fibrotic Effect On Coronavirus Infection

PRO
Brookline Capital Initiates Coverage On Hepion Pharmaceuticals with Buy Rating, Announces $12 Price Target